BG Medicine, Inc.

Beyond Genomics Appoints Stelios Papadopoulos to its Board of Directors

Beyond Genomics Appoints Stelios Papadopoulos to its Board of Directors

March 2, 2004

WALTHAM, MA - March 2, 2004 - Beyond Genomics, Inc. today announced the appointment of Stelios Papadopoulos, Ph.D., to its Board of Directors. Dr. Papadopoulos is a Vice Chairman of SG Cowen Securities Corporation and an investment banker focused on the biotechnology and pharmaceutical sectors.

Adnexus Therapeutics

Compound Therapeutics, Inc. Announces Acquisition of Strategic Assets of Phylos, Inc.

Compound Therapeutics, Inc. Announces Acquisition of Strategic Assets of Phylos, Inc.

March 9, 2004

A New Generation of Oncology Products to be Advanced in Anti-Angiogenesis Program

WALTHAM, Mass. - March 9, 2004 - Compound Therapeutics, Inc., a biotechnology company leading the development of a new generation of high-potency targeted protein-based drugs, today confirmed details of its acquisition of strategic assets of Phylos, Inc., and announced the advancement of a preclinical oncology program in anti-angiogenesis.

Zalicus

CombinatoRx Raises $30 Million In Third Venture Capital Round

CombinatoRx Raises $30 Million In Third Venture Capital Round

March 10, 2004

Proceeds from Financing to Support Clinical Evaluation of Novel Anti-Inflammatory and Oncology Products

Pervasis Therapeutics, Inc.

A New Attack On Complex Diseases

A New Attack On Complex Diseases

March 15, 2004

By Jeffrey Krasner, Globe Staff, 3/15/2004

Three of the best-known scientists in the field of tissue engineering have teamed up with two leading life-science venture capital firms to launch a company that plans to combine elements of tissue engineering and cell-based therapy with the precision of medical devices to attack a variety of human diseases.

TripAdvisor LLC

IAC Acquires TripAdvisor, Inc.

IAC Acquires TripAdvisor, Inc.

March 16, 2004

Leading Travel Research Site Empowers Consumers with Information and Savings Advice; Will Join IAC Local and Media Services Group

NEW YORK, NY - March 16, 2004 - IAC/InterActiveCorp (Nasdaq: IACI) today announced that the company has agreed to acquire TripAdvisor, Inc., the leading travel research site. Terms of the agreement were not disclosed.

Morphotek, Inc.

Morphotek Achieves Collaboration Milestone with the Successful Development of Antibody Cell Line for Centocor

Morphotek Achieves Collaboration Milestone with the Successful Development of Antibody Cell Line for Centocor

April 6, 2004

Exton, PA - April 6, 2004Ð Morphotek Inc. announced today that Centocor, Inc. of Malvern, PA, has confirmed the development of a high-titer antibody producing cell line from the companies' research collaboration. The development resulted in an undisclosed milestone payment to Morphotek.

e-Dialog, Inc.

e-Dialog and Miles Kimball Win Gold Medal for Creative Excellence at 2004 NEDMA Awards

e-Dialog and Miles Kimball Win Gold Medal for Creative Excellence at 2004 NEDMA Awards

April 13, 2004

LEXINGTON, MA - April 13, 2004 -- e-Dialog, the precision e-mail marketing innovator, won a first place Gold Medal for creative excellence in the Consumer e-Mail Marketing category on behalf of their client, Miles Kimball, a leading direct marketer of consumer gifts and household products. NEDMA, the New England Direct Marketing Association, held the 41st annual awards ceremony at The Roxy, in Boston, MA on April 8, 2004. This award marks e-Dialog's third consecutive annual award from NEDMA.

Selventa

Genstruct Appoints William M. Ladd Ph.D. Vice President of Discovery Systems

Genstruct Appoints William M. Ladd Ph.D. Vice President of Discovery Systems

April 15, 2004

CAMBRIDGE, Mass., April 15 /PRNewswire/ -- Genstruct Inc., a biotechnology company that develops computable biological models to determine compound mechanisms of action and identify biomarkers for drug discovery and development, today announced the appointment of William M. Ladd, Ph.D. as Vice President - Discovery Systems. Dr. Ladd will lead development of the company's Molecular Epistemics(TM) Platform and Global Knowledge Repository.

Ensemble Therapeutics Corporation

Ensemble Discovery Corporation Announces $15M Series A Preferred Financing

Ensemble Discovery Corporation Announces $15M Series A Preferred Financing

May 12, 2004

Cutting edge approach will revolutionize chemical discovery

Morphotek, Inc.

Morphotek Announces Collaborative Agreement with Tanox to Develop High-Titer Production Cells for the Manufacturing of Therapeutic Antibodies Using Suppressor of Immunoglobulin Product (SIP) Technology

Morphotek Announces Collaborative Agreement with Tanox to Develop High-Titer Production Cells for the Manufacturing of Therapeutic Antibodies Using Suppressor of Immunoglobulin Product (SIP) Technology

June 7, 2004

Exton, PA, June 7, 2004 -- Morphotek Inc. announced today that it has signed a collaborative research agreement with Tanox, Inc. (NASDAQ: TNOX) of Houston, TX, for the use of Morphotek's proprietary SIP Technology to develop universal high-titer mammalian cell line hosts for the commercial manufacturing of therapeutic antibody products.